HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Ioxaglic Acid (Ioxaglate Meglumine)

Subscribe to New Research on Ioxaglic Acid

A low-osmolar, ionic contrast medium used in various radiographic procedures.

Also Known As:

Ioxaglate Meglumine; Ioxaglate Sodium; Hexabrix; Ioxaglic Acid Monosodium Salt; Ioxaglic Acid, Calcium Salt (2:1); Methylglucamine Ioxaglate; P-286 (Contrast Media); P286 (Contrast Media); Ioxaglate, Methylglucamine; Meglumine, Ioxaglate; Ioxaglate; Benzoic acid, 3-((((3-(acetylmethylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)benzoyl)amino)acetyl)amino)-5-(((2-hydroxyethyl)amino)carbonyl)-2,4,6-triiodo-

Networked: 190 relevant articles (12 outcomes, 21 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Carboxylic Acids: 83
  - Carbocyclic Acids
    - Benzoic Acids: 18
      - Benzoic Acid: 304
        Benzoates: 268
        Iodobenzoates
        Triiodobenzoic Acids: 2
        Ioxaglic Acid: 190

Experts

1.	Papadopoulou, Maria V: 2 articles (10/2014 - 06/2014)
2.	Li, Lu-Ping: 2 articles (10/2014 - 06/2014)
3.	Solomon, Richard: 2 articles (10/2014 - 06/2014)
4.	Franklin, Tammy: 2 articles (10/2014 - 06/2014)
5.	Prasad, Pottumarthi V: 2 articles (10/2014 - 06/2014)
6.	Zhou, Ying: 2 articles (10/2014 - 06/2014)
7.	Lu, Jing: 2 articles (10/2014 - 06/2014)
8.	Bergqvist, David: 2 articles (02/2005 - 01/2005)
9.	Liss, Per: 2 articles (02/2005 - 01/2005)
10.	Hellberg, Olof: 2 articles (02/2005 - 01/2005)

Related Diseases

1.	Pain (Aches) 09/01/1996 - "Patients receiving ioxaglate reported a significantly greater incidence of injection-related pain (p = .025). " 03/01/1987 - "There was a significant reduction in the degree of pain experienced by the Ioxaglate group compared to the reference group (p less than 0.001). " 03/01/1987 - "The patients in the Hexabrix group had a mean pain score of 1.3 compared to the patients in the Renografin-76 group who had a mean pain score of 6.1. " 01/01/1987 - "A lower incidence of heat and pain in patients receiving Hexabrix was believed to be related to its lower osmolality. " 02/01/1986 - "Excellent patient tolerance was achieved with less pain on injection with Hexabrix. "
2.	Brain Neoplasms (Brain Tumor) 11/01/1984 - "The monoionic dimer ioxaglate is as effective as iothalamate for enhancement of canine brain tumors." 07/01/1984 - "The monoionic dimer ioxaglate is as effective as iothalamate for enhancement of canine brain tumors." 11/01/1984 - "The magnitude and time course of contrast enhancement in spontaneous canine brain tumors was determined for two contrast agents: meglumine iothalamate and sodium meglumine ioxaglate. " 07/01/1984 - "The magnitude and time course of contrast enhancement in spontaneous canine brain tumors was determined for two contrast agents: meglumine iothalamate and sodium meglumine ioxaglate. "
3.	Renal Insufficiency (Renal Failure) 11/01/1986 - "Determination of changes in plasma concentration of ioxaglate in patients with renal failure made it possible to demonstrate that distribution and clearance of this contrast medium, as in the case of classic uroangiographic products, conform to an open two-compartment model with clearance from the central compartment. " 11/01/1986 - "Pharmacokinetic study of ioxaglate, a low osmolality contrast medium, in patients with renal failure." 11/01/2006 - "Ioxaglate-treated patients had a significantly lower renal failure incidence (0.8%, P<0.001). " 11/01/2006 - "Iohexol-treated patients had a similar low risk for developing clinically significant renal failure (0.9%) as ioxaglate. " 11/01/2006 - "In conclusion, risk of developing renal failure and required dialysis after coronary procedures is higher when patients received iodixanol than ioxaglate or iohexol."
4.	Nausea 11/01/1994 - "[The mechanism producing nausea during ventriculography performed with ioxaglate: the implications of a randomized study]." 11/01/1994 - "The mechanism of ioxaglate-induced nausea has not been fully elucidated. " 05/01/1996 - "Nausea/vomiting occurred significantly more frequent with ioxaglate; no further clinically relevant differences were detected." 11/01/1990 - "In conclusion, both low osmolar CM were well tolerated, but Hexabrix caused more transient nausea or vomiting. " 03/01/1986 - "Nausea was reported in four patients after injection of Hexabrix, and a metallic taste was significantly more frequent (p less than 0.01) with this contrast medium. "
5.	Acute Coronary Syndrome 11/01/2002 - "In patients with an acute coronary syndrome, there was a trend toward a reduced incidence of the combined endpoint in the Hexabrix compared to the Visipaque group, although this did not reach statistical significance (17.2% vs. 24.8%; P = 0.17). "

Related Drugs and Biologics

1.	iodixanol (Visipaque)
2.	Iothalamic Acid (Iotalamic Acid)
3.	Contrast Media
4.	Iopamidol (Isovue)
5.	Diatrizoate (Hypaque)
6.	iopentol
7.	Iodine
8.	Serotonin (5 Hydroxytryptamine)
9.	Metoclopramide (Reglan)
10.	Epinephrine (Adrenaline)

Related Therapies and Procedures

1.	Injections
2.	Intra-Arterial Injections
3.	Transplants (Transplant)
4.	Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)
5.	Angioplasty (Angioplasty, Transluminal)